版本:
中国

BRIEF-Valeritas' V-GO wearable insulin delivery device provided significant and sustained A1C reductions

May 4 Valeritas Holdings Inc

* Valeritas V-GO wearable insulin delivery device provided significant and sustained A1C reductions and achieved a1c glycemic targets in patients with type 2 diabetes Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐